A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease

Klatt, S., Doecke, J.D., Roberts, A., Boughton, B.A.ORCID: 0000-0001-6342-9814, Masters, C.L., Horne, M. and Roberts, B.R. (2021) A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. npj Parkinson's Disease, 7 (1). Art. 94.

Abstract

Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer’s disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic.

Item Type:	Journal Article
Murdoch Affiliation(s):	Australian National Phenome Center
Publisher:	Nature Publishing Group
Copyright:	© 2021 The Authors.
URI:	http://researchrepository.murdoch.edu.au/id/eprint/62670

Item Control Page

Downloads